Dimexid® (Solution, Gel, Concentrate) Instructions for Use
ATC Code
M02AX03 (Dimethyl sulfoxide)
Active Substance
Dimethyl sulfoxide (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Drug with anti-inflammatory and analgesic action for external use
Pharmacotherapeutic Group
Drugs for external use for muscle and joint pain; other drugs for external use for muscle and joint pain
Pharmacological Action
Anti-inflammatory agent for external use. The mechanism of action is associated with the inactivation of hydroxyl radicals and the improvement of metabolic processes in the focus of inflammation, as well as a decrease in the conduction rate of excitatory impulses in peripheral neurons.
It has a local anesthetic, local anti-inflammatory, analgesic, and antimicrobial effect; it possesses some fibrinolytic activity. It penetrates the skin and other biological membranes, increasing their permeability to medicinal substances.
Pharmacokinetics
When a solution of dimethyl sulfoxide is applied to the skin, it is detected in the blood within 5 minutes, with Cmax reached in 4-6 hours, maintaining an almost unchanged level for 1.5-3 days.
Dimethyl sulfoxide is excreted in urine and feces, both unchanged and in the form of dimethyl sulfone.
Indications
As part of complex therapy: diseases of the musculoskeletal system: rheumatoid arthritis, ankylosing spondylitis (Bekhterev’s disease), deforming osteoarthritis (with damage to periarticular tissues), reactive synovitis, limited scleroderma, erythema nodosum, discoid lupus erythematosus, foot mycoses, keloid scars, thrombophlebitis, alopecia, eczema, streptoderma, erysipelas; bruises, sprains, traumatic infiltrates; purulent wounds, burns, radiculitis, trophic ulcers, acne, furunculosis; in skin-plastic surgery – for the preservation of skin homografts.
ICD codes
| ICD-10 code | Indication |
| A46 | Erysipelas |
| B35.3 | Tinea pedis |
| I80 | Phlebitis and thrombophlebitis |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L08.0 | Pyoderma |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L30.0 | Nummular eczema |
| L52 | Erythema nodosum |
| L63.9 | Alopecia areata, unspecified |
| L64.9 | Androgenic alopecia, unspecified |
| L70 | Acne |
| L91.0 | Hypertrophic scar |
| L93.0 | Discoid lupus erythematosus |
| L94.0 | Localized scleroderma [morphea] |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| M05 | Seropositive rheumatoid arthritis |
| M15 | Polyosteoarthritis |
| M45 | Ankylosing spondylitis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M65 | Synovitis and tenosynovitis |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.3 | Dislocation, sprain and strain of joint and ligament of unspecified body region |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1F28.2 | Dermatophytosis of foot |
| 8B93.Z | Radiculopathy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| 9A06.70 | Atopic eczema of the eyelids |
| BD70.0 | Superficial thrombophlebitis of lower extremities |
| BD70.Z | Superficial thrombophlebitis, unspecified |
| BD71.4 | Deep vein thrombosis of lower extremity |
| BD7Z | Diseases of veins, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA82 | Nummular dermatitis |
| EA85.20 | Atopic hand eczema |
| EB21 | Pyoderma gangrenosum |
| EB31 | Erythema nodosum |
| EB61.0 | Localized scleroderma |
| ED70.1 | Female pattern hair loss |
| ED70.2Z | Alopecia areata, unspecified |
| ED80.Z | Acne, unspecified |
| EE60.1 | Hypertrophic scar |
| EF60 | Ischemic ulceration of the skin |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| EL50.0 | Postoperative keloid scar |
| EL50.1 | Postoperative hypertrophic scar |
| EM0Z | Unspecified skin disorder |
| FA05 | Polyosteoarthritis |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB40.Z | Tenosynovitis, unspecified |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.3 | Dislocation, sprain or strain of unspecified body region |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution, Concentrate
For external use. In the form of applications and irrigations (washings). The concentration of the solution and the solvent are determined depending on the area of application. The duration of treatment is 10-15 days.
Gel
For external use.
Adults and children over 12 years: the drug is applied in a thin layer to the affected area 1-2 times/day and rubbed in lightly. The duration of treatment is 10-14 days. Repeated courses are recommended to be conducted no less than 10 days apart.
Adverse Reactions
Possible: allergic reactions, pruritic dermatitis, contact dermatitis, erythema, dry skin, mild burning sensation, pruritic dermatitis.
Rarely: bronchospasm.
Contraindications
Hypersensitivity to dimethyl sulfoxide; severe hepatic and/or renal failure, angina pectoris, severe atherosclerosis, glaucoma, cataract, stroke, coma, myocardial infarction; pregnancy; breastfeeding period; children under 12 years of age.
Use in Pregnancy and Lactation
Dimethyl sulfoxide is contraindicated for use during pregnancy and breastfeeding.
Use in Hepatic Impairment
Contraindicated in severe hepatic failure.
Use in Renal Impairment
Contraindicated in severe renal failure.
Pediatric Use
Contraindicated for use in children under 12 years of age.
Special Precautions
Dimethyl sulfoxide should be used with caution simultaneously with other medicinal products, as it may enhance their effect.
Before using dimethyl sulfoxide, it is recommended to perform a test for drug tolerance.
Drug Interactions
Dimethyl sulfoxide can be used in combination with heparin, antibiotics, and NSAIDs in dosage forms for external use.
It increases the absorption and enhances the effect of ethanol and insulin.
It increases the sensitivity of microorganisms to aminoglycoside and beta-lactam antibiotics, chloramphenicol, rifampicin, griseofulvin.
It sensitizes the body to agents for general anesthesia.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Concentrate for solution for external use: fl. 50 ml or 100 ml
Marketing Authorization Holder
Scan Biotech LLC (India)
Dosage Form
 |
Dimexid® | Concentrate for solution for external use: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless transparent liquid or colorless crystals, odorless or with a weak specific odor; hygroscopic.
| 100 ml | |
| Dimethyl sulfoxide | 99 g |
50 ml – amber glass bottles (1) – cardboard packs.
100 ml – amber glass bottles (1) – cardboard packs.
Gel for external use 25%: tube 30 g or 50 g
Marketing Authorization Holder
Biopharmaks, LLC (Russia)
Manufactured By
AVZ S-P. LLC (Russia)
Or
Pharmamed, LLC (Russia)
Contact Information
PHARMAMED LLC (Russia)
Dosage Form
 |
Dimexid® | Gel for external use 25%: tube 30 g or 50 g |
Dosage Form, Packaging, and Composition
Gel for external use colorless or with a yellowish tint, transparent, homogeneous, with a weak specific odor; the presence of air bubbles is allowed.
| 100 g | |
| Dimethyl sulfoxide | 25 g |
Excipients: methylparahydroxybenzoate, propylparahydroxybenzoate, carbomer, sodium hydroxide solution 5%, purified water.
30 g – laminated tubes (1) – cardboard packs.
50 g – laminated tubes (1) – cardboard packs.
Concentrate for solution for external use: fl. 50 ml or 100 ml
Marketing Authorization Holder
Begrif, LLC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless transparent liquid or colorless crystals, odorless or with a weak characteristic odor, hygroscopic.
| 1 ml | |
| Dimethyl sulfoxide | 1 ml |
50 ml – amber glass bottles (1) – cardboard packs.
100 ml – amber glass bottles (1) – cardboard packs.
50 ml – amber glass dropper bottles (1) – cardboard packs.
100 ml – amber glass dropper bottles (1) – cardboard packs.
Concentrate for solution for external use 99%: 50 ml or 100 ml fl.
Marketing Authorization Holder
West, LLC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: 50 ml or 100 ml fl. |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless transparent hygroscopic liquid or colorless crystals, odorless or with a weak specific odor.
| 100 ml | |
| Dimethyl sulfoxide | 99 g |
50 ml – dark glass bottles (1) – cardboard packs.
100 ml – dark glass bottles (1) – cardboard packs.
50 ml – dark glass bottles (70) – cardboard boxes (for hospitals).
100 ml – dark glass bottles (50) – cardboard boxes (for hospitals).
5 kg – polyethylene canisters (for hospitals).
Concentrate for solution for external use: fl. 50 ml or 100 ml, drum 20 kg
Marketing Authorization Holder
Khimreaktivkomplekt Plant, JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use: fl. 50 ml or 100 ml, drum 20 kg |
Dosage Form, Packaging, and Composition
| Concentrate for solution for external use | 100 ml |
| Dimethyl sulfoxide | 99 g |
50 ml – bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml
Marketing Authorization Holder
Ivanovo Pharmaceutical Factory PJSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless, transparent liquid or colorless crystals, odorless or with a weak specific odor; hygroscopic.
| 1 fl. | |
| Dimethyl sulfoxide | 99% |
50 ml – dark glass bottles (1) – cardboard packs.
100 ml – dark glass bottles (1) – cardboard packs.
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml, dropper fl. 100 ml
Marketing Authorization Holder
Kemerovo Pharmaceutical Factory JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml, dropper fl. 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless, transparent liquid or colorless crystals, odorless or with a weak specific odor; hygroscopic.
| 100 ml | |
| Dimethyl sulfoxide | 99 g |
50 ml – glass bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
100 ml – dropper bottles (1) – cardboard packs.
Concentrate for solution for external use: fl. 50 ml or 100 ml
Marketing Authorization Holder
Kirov Pharmaceutical Factory, JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use in the form of a colorless transparent liquid or colorless crystals, odorless or with a weak characteristic odor, hygroscopic.
| 100 ml | |
| Dimethyl sulfoxide | 100 ml |
50 ml – dark glass bottles (1) – cardboard packs.
100 ml – dark glass bottles (1) – cardboard packs.
50 ml – polyethylene terephthalate bottles (1) – cardboard packs.
100 ml – polyethylene terephthalate bottles (1) – cardboard packs.
Solution for external use 25%: fl. 100 g, 150 g, 200 g, 250 g, 300 g, or 500 g
Marketing Authorization Holder
Lekar, LLC (Russia)
Dosage Form
|
Dimexid® | Solution for external use 25%: fl. 100 g, 150 g, 200 g, 250 g, 300 g, or 500 g |
Dosage Form, Packaging, and Composition
Solution for external use colorless, transparent, odorless or with a faint specific odor.
| 1 fl. | |
| Dimethyl sulfoxide | 100 g, 150 g, 200 g, 250 g, 300 g, 500 g |
100 g – bottles – carton packs.
150 g – bottles – carton packs.
200 g – bottles – carton packs.
250 g – bottles – carton packs.
300 g – bottles – carton packs.
500 g – bottles – carton packs.
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml
Marketing Authorization Holder
Marbiopharm, JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for external use 99% | 100 ml |
| Dimethyl sulfoxide | 99 g |
50 ml – dark glass bottles (1) – carton packs.
100 ml – bottles (1) – carton packs.
Concentrate for solution for external use 99%: fl. 100 ml
Marketing Authorization Holder
Murom Instrument-Making Plant, FSUE (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 100 ml |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for external use 99% | 100 ml |
| Dimethyl sulfoxide | 99 g |
100 ml – dark glass bottles (1) – carton packs.
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml
Marketing Authorization Holder
Redkinsky Pilot Plant, PJSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for external use 99% | 100 ml |
| Dimethyl sulfoxide | 99 g |
50 ml – dark glass bottles (1) – carton packs.
100 ml – dark glass bottles (1) – carton packs.
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml
Marketing Authorization Holder
Tatkhimpharmpreparaty, JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for external use 99% | 100 ml |
| Dimethyl sulfoxide | 99 g |
50 ml – dark glass bottles (1) – carton packs.
100 ml – bottles (1) – carton packs.
Concentrate for solution for external use 99%: 50 ml or 100 ml fl.
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: 50 ml or 100 ml fl. |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for external use | 100 ml |
| Dimethyl sulfoxide | 99 g |
50 ml – bottles (1) – carton packs.
100 ml – bottles (1) – carton packs.
Concentrate for preparation of solution for external use: 50 ml or 100 ml bottle.
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Dimexid® | Concentrate for preparation of solution for external use: 50 ml or 100 ml bottle. |
Dosage Form, Packaging, and Composition
Concentrate for preparation of solution for external use in the form of a colorless, transparent liquid or colorless crystals, odorless or with a faint specific odor, hygroscopic.
| 100 ml | |
| Dimethyl sulfoxide | 100 ml |
50 ml – bottles (1) – carton packs.
100 ml – bottles (1) – carton packs.
50 ml – bottles (20) – carton boxes (for hospitals).
50 ml – bottles (40) – carton boxes (for hospitals).
50 ml – bottles (50) – carton boxes (for hospitals).
50 ml – bottles (60) – carton boxes (for hospitals).
50 ml – bottles (80) – carton boxes (for hospitals).
50 ml – bottles (100) – carton boxes (for hospitals).
50 ml – bottles (120) – carton boxes (for hospitals).
100 ml – bottles (20) – carton boxes (for hospitals).
100 ml – bottles (40) – carton boxes (for hospitals).
100 ml – bottles (50) – carton boxes (for hospitals).
100 ml – bottles (60) – carton boxes (for hospitals).
Concentrate for solution for external use 99%: fl. 50 ml or 100 ml
Marketing Authorization Holder
Formula-FR, LLC (Russia)
Manufactured By
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Dimexid® | Concentrate for solution for external use 99%: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for preparation of solution for external use – a colorless transparent liquid or colorless crystals, odorless or with a faint specific odor; hygroscopic.
| 100 ml | |
| Dimethyl sulfoxide | 99 ml |
50 ml – bottles (1) – carton packs.
100 ml – bottles (1) – carton packs.
Concentrate for preparation of solution for external use: 50 ml or 100 ml bottle.
Marketing Authorization Holder
YUGPHARM, LLC (Russia)
Dosage Form
|
Dimexid® | Concentrate for preparation of solution for external use: 50 ml or 100 ml bottle. |
Dosage Form, Packaging, and Composition
Concentrate for preparation of solution for external use in the form of a colorless transparent hygroscopic liquid or colorless crystals, odorless or with a faint specific odor.
| 100 ml | |
| Dimethyl sulfoxide | 100 g |
50 ml – glass bottles (1) – carton packs.
100 ml – glass bottles (1) – carton packs.
50 ml – glass bottles (1) (from 4 to 100 pcs) – group packaging (for hospitals).
100 ml – glass bottles (1) (from 4 to 100 pcs) – group packaging (for hospitals).
1 L – canisters for hospitals.
1 L – canisters (2) – group packaging (for hospitals).
1 L – canisters (3) – group packaging (for hospitals).
1 L – canisters (4) – group packaging (for hospitals).
1 L – canisters (5) – group packaging (for hospitals).
1 L – canisters (6) – group packaging (for hospitals).
1 L – canisters (7) – group packaging (for hospitals).
1 L – canisters (8) – group packaging (for hospitals).
1 L – canisters (9) – group packaging (for hospitals).
1 L – canisters (10) – group packaging (for hospitals).
1 L – canisters (11) – group packaging (for hospitals).
1 L – canisters (12) – group packaging (for hospitals).
3 L – canisters for hospitals.
3 L – canisters (2) – group packaging (for hospitals).
3 L – canisters (3) – group packaging (for hospitals).
3 L – canisters (4) – group packaging (for hospitals).
3 L – canisters (5) – group packaging (for hospitals).
3 L – canisters (6) – group packaging (for hospitals).
3 L – canisters (7) – group packaging (for hospitals).
3 L – canisters (8) – group packaging (for hospitals).
3 L – canisters (9) – group packaging (for hospitals).
3 L – canisters (10) – group packaging (for hospitals).
3 L – canisters (11) – group packaging (for hospitals).
3 L – canisters (12) – group packaging (for hospitals).
5 L – canisters for hospitals.
5 L – canisters (2) – group packaging (for hospitals).
5 L – canisters (3) – group packaging (for hospitals).
5 L – canisters (4) – group packaging (for hospitals).
5 L – canisters (5) – group packaging (for hospitals).
5 L – canisters (6) – group packaging (for hospitals).
5 L – canisters (7) – group packaging (for hospitals).
5 L – canisters (8) – group packaging (for hospitals).
5 L – canisters (9) – group packaging (for hospitals).
5 L – canisters (10) – group packaging (for hospitals).
5 L – canisters (11) – group packaging (for hospitals).
5 L – canisters (12) – group packaging (for hospitals).
Concentrate for solution for external use
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Dimexid® Renewal | Concentrate for solution for external use |
Dosage Form, Packaging, and Composition
Concentrate for solution for external use
| 1 fl. | |
| Dimethyl sulfoxide | 100% |
100 ml – bottles – carton packs – Over-the-Counter
50 ml – bottles – carton packs – Over-the-Counter
Gel for external use 25%
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Dimexid®-Tphf | Gel for external use 25% |
Dosage Form, Packaging, and Composition
Gel for external use
| 100 g | |
| Dimethyl sulfoxide | 25 g |
30 g – tubes – carton packs – Over-the-Counter
40 g – tubes – carton packs – Over-the-Counter
50 g – tubes – carton packs – Over-the-Counter
![Dimexid® [Solution, Gel, Concentrate] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Dimexid® [Solution, Gel, Concentrate] 2")